These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29059166)

  • 1. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.
    Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J
    Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
    Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
    J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vimentin loss promotes cancer proliferation through up-regulating Rictor/AKT/β-catenin signaling pathway.
    Ding Y; Lv C; Zhou Y; Zhang H; Zhao L; Xu Y; Fan X
    Exp Cell Res; 2021 Aug; 405(1):112666. PubMed ID: 34052237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTORC2-mediated direct phosphorylation regulates YAP activity promoting glioblastoma growth and invasive characteristics.
    Holmes B; Benavides-Serrato A; Saunders JT; Kumar S; Nishimura RN; Gera J
    Neoplasia; 2021 Sep; 23(9):951-965. PubMed ID: 34343821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
    Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
    Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth
    Hwang Y; Kim LC; Song W; Edwards DN; Cook RS; Chen J
    Cancer Res; 2019 Jul; 79(13):3178-3184. PubMed ID: 31085701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.
    Benavides-Serrato A; Lee J; Holmes B; Landon KA; Bashir T; Jung ME; Lichtenstein A; Gera J
    PLoS One; 2017; 12(4):e0176599. PubMed ID: 28453552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway.
    Liang X; Sun R; Zhao X; Zhang Y; Gu Q; Dong X; Zhang D; Sun J; Sun B
    J Cell Mol Med; 2017 Dec; 21(12):3579-3591. PubMed ID: 28699701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells.
    Das G; Shiras A; Shanmuganandam K; Shastry P
    Mol Carcinog; 2011 Jun; 50(6):412-23. PubMed ID: 21557327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma.
    Akgül S; Li Y; Zheng S; Kool M; Treisman DM; Li C; Wang Y; Gröbner S; Ikenoue T; Shen Y; Camelo-Piragua S; Tomasek G; Stark S; Guduguntla V; Gusella JF; Guan KL; Pfister SM; Verhaak RGW; Zhu Y
    Cell Rep; 2018 Jul; 24(2):463-478.e5. PubMed ID: 29996106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ig superfamily protein PTGFRN coordinates survival signaling in glioblastoma multiforme.
    Aguila B; Morris AB; Spina R; Bar E; Schraner J; Vinkler R; Sohn JW; Welford SM
    Cancer Lett; 2019 Oct; 462():33-42. PubMed ID: 31377205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/Akt promotes feedforward mTORC2 activation through IKKα.
    Dan HC; Antonia RJ; Baldwin AS
    Oncotarget; 2016 Apr; 7(16):21064-75. PubMed ID: 27027448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
    Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
    Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
    Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.